Weil Company Inc. Purchases 3,298 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Weil Company Inc. raised its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 259.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,570 shares of the biotechnology company's stock after purchasing an additional 3,298 shares during the period. Weil Company Inc.'s holdings in United Therapeutics were worth $1,409,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. State of Michigan Retirement System boosted its holdings in United Therapeutics by 1.6% in the first quarter. State of Michigan Retirement System now owns 12,432 shares of the biotechnology company's stock worth $3,832,000 after acquiring an additional 200 shares in the last quarter. Alps Advisors Inc. increased its stake in United Therapeutics by 10.4% during the 1st quarter. Alps Advisors Inc. now owns 1,116 shares of the biotechnology company's stock valued at $344,000 after purchasing an additional 105 shares in the last quarter. Rehmann Capital Advisory Group bought a new stake in United Therapeutics during the 1st quarter valued at $562,000. Crossmark Global Holdings Inc. increased its stake in United Therapeutics by 3.5% during the 1st quarter. Crossmark Global Holdings Inc. now owns 3,645 shares of the biotechnology company's stock valued at $1,124,000 after purchasing an additional 123 shares in the last quarter. Finally, TD Private Client Wealth LLC increased its stake in United Therapeutics by 29.8% during the 1st quarter. TD Private Client Wealth LLC now owns 4,762 shares of the biotechnology company's stock valued at $1,468,000 after purchasing an additional 1,092 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $4.64 on Friday, reaching $295.52. 300,699 shares of the company traded hands, compared to its average volume of 444,965. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The company has a 50 day moving average of $301.04 and a 200 day moving average of $320.31. The firm has a market capitalization of $13.33 billion, a PE ratio of 11.79, a PEG ratio of 6.57 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business's revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the company posted $6.17 earnings per share. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 3,000 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the sale, the director owned 1,750 shares of the company's stock, valued at $499,747.50. The trade was a 63.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director directly owned 4,883 shares in the company, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 76,681 shares of company stock valued at $22,813,739. 10.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Morgan Stanley dropped their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday. Cantor Fitzgerald initiated coverage on United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Bank of America decreased their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. Finally, UBS Group decreased their price target on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a report on Monday, June 30th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $383.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.